BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Inc. Begins Assembly of New Production

[Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line Increases overall capacity by $30 million annually and paves way for entrance into the Military Pharmaceutical Market XIANYANG, China, May 25, 2010 (Xinhua-PRNewswire-FirstCall) BSPM News Biostar completed Chinese Military Drug Administration clinical trials for Zushima Analgesic Aerosol Spray (“Zushima”) in April through the Chinese No. 4 Military Medical University. Zushima is]

By | 2016-03-03T14:23:29+00:00 May 25th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[Biostar Pharmaceuticals, Beginssembly of New Production Linereases overallpacity by $30 million annually and paves way for entrance into the Military Pharmaceutical Market XIANYANG, China, May 25, 2010 (Xinhua-PRNewswire-FirstCall) BSPM News Biostarmpleted Chinese Military Drugministration clinical trials for Zushima Analgesicrosolray (Zushima) in April through the Chinese No. 4 Military Medical University. Zushima is a traditional Chinese]

By | 2016-02-07T17:23:04+00:00 May 25th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Beginssembly of New Production Linereases overallpacity

[Biostar Pharmaceuticals, Beginssembly of New Production Linereases overallpacity by $30 million annually and paves way for entrance into the Military Pharmaceutical Market XIANYANG, China, May 25, 2010 (Xinhua-PRNewswire-FirstCall) BSPM News Biostarmpleted Chinese Military Drugministration clinical trials for Zushima Analgesicrosolray (Zushima) in April through the Chinese No. 4 Military Medical University. Zushima is a traditional Chinese]

By | 2016-02-07T17:23:59+00:00 May 25th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BIOSTAR PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS XIANYANG, China, May 17, 2010 (Xinhua-PRNewswire-FirstCall) - Q1 2010 revenue increased 66.0% to $12.4 million - Q1 gross margins were 77.0%, a 1,270-basis point improvement - Q1 2010 Non-GAAP adjusted net income increased 32.1% to $2.4 million with adjusted EPS of $0.09 - Biostar reiterates guidance for 2010: Revenue expected to]

By | 2016-03-03T14:24:38+00:00 May 17th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2010 FINANCIAL

[BIOSTAR PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS XIANYANG, China, May 17, 2010 (Xinhua-PRNewswire-FirstCall) - Q1 2010 revenue increased 66.0% to $12.4 million - Q1 gross margins were 77.0%, a 1,270-basis point improvement - Q1 2010 Non-GAAP adjusted net income increased 32.1% to $2.4 million with adjusted EPS of $0.09 - Biostar reiterates guidance for 2010: Revenue expected to]

By | 2016-03-03T14:25:40+00:00 May 17th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: BIOSTAR PHARMACEUTICALS, ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

[BIOSTAR PHARMACEUTICALS, ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS XIANYANG, China, May 17, 2010 (Xinhua-PRNewswire-FirstCall) - Q1 2010 revenuereased 66.0% to $12.4 million - Q1 gross margins were 77.0%, a 1,270-basis point improvement - Q1 2010 Non-GAAPjusted netomereased 32.1% to $2.4 million withjusted EPS of $0.09]

By | 2016-02-07T17:25:35+00:00 May 17th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[BIOSTAR PHARMACEUTICALS, ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS XIANYANG, China, May 17, 2010 (Xinhua-PRNewswire-FirstCall) - Q1 2010 revenuereased 66.0% to $12.4 million - Q1 gross margins were 77.0%, a 1,270-basis point improvement - Q1 2010 Non-GAAPjusted netomereased 32.1% to $2.4 million withjusted EPS of $0.09]

By | 2016-02-07T17:25:04+00:00 May 17th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x March 31, 2010 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [ASSETS ACQUISITION AGREEMENT Party A: Shaanxi Biostar Biotech, Ltd. Legal Representative: WANG Ronghua Party B: Xi’an Meipude Bio-Technology Co., Ltd. Legal Representative: SUN Yaomei On March 28, 2010, Party A and Party B again entered into the following agreement concerning Party A’s acquisition of Party B’s assets. A. Party B agrees to transfer all of the technologies and assets of] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Elaine Zhao Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 ex32-2.htm]

By | 2016-03-03T14:27:06+00:00 May 14th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q (Mark One) x March 31, 2010

[FORM 10-Q (Mark One) x March 31, 2010 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [ASSETS ACQUISITION AGREEMENT Party A: Shaanxi Biostar Biotech, Ltd. Legal Representative: WANG Ronghua Party B: Xi’an Meipude Bio-Technology Co., Ltd. Legal Representative: SUN Yaomei On March 28, 2010, Party A and Party B again entered into the following agreement concerning Party A’s acquisition of Party B’s assets. A. Party B agrees to transfer all of the technologies and assets of] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Elaine Zhao Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 ex32-2.htm]

By | 2016-03-03T14:29:02+00:00 May 14th, 2010|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x March 31, 2010 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [ASSETS ACQUISITIONREEMENT Party A:Shaanxi Biostar Biotech, Legal Representative:WANG Ronghua Party B: Xian Meipude Bio-Technology Legal Representative:SUN Yaomei On March 28, 2010, Party A and Party Bain entered into the followingreementncerning Party acquisition of Party Bssets. A. Party Brees to transferl of the technologies andsets of Xian Meipude Bio-Technology to Party A, and Party Arees to] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Ronghua Wang Chief Executive Officer ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. Elaine Zhao Chief Financial Officer (Principal Financial and Accounting Officer) ex32-2.htm 6 EX-32.2]

By | 2016-02-07T17:26:38+00:00 May 14th, 2010|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar